A moderated discussion by speakers from the pharmaceutical industry, regulatory and academics, highlighting current trends and recent work. This session explores how industry and health systems can better engage healthcare providers in preventing, detecting, and reporting substandard and falsified medical products (SFMPs). Speakers will share perspectives on strengthening provider training, leveraging technology for traceability, and improving collaboration between industry, regulators, and clinicians. Discussions will highlight oncology drug safety, digital verification tools, and lessons from India's response to recent SFMP incidents. The session emphasizes integrating medicine quality assurance into patient safety and building more resilient health systems through cross-sector partnerships.
A moderated discussion by speakers from the pharmaceutical industry, regulatory and academics, highlighting current trends and recent work. This session explores how industry and health systems can better engage healthcare providers in preventing, detecting, and reporting substandard and falsified medical products (SFMPs). Speakers will share perspectives on strengthening provider training, leveraging technology for traceability, and improving collaboration between industry, regulators, and clinicians. Discussions will highlight oncology drug safety, digital verification tools, and lessons from India's response to recent SFMP incidents. The session emphasizes integrating medicine quality assurance into patient safety and building more resilient health systems through cross-sector partnerships.
BESAFE2025 besafe@jh.eduTechnical Issues?
If you're experiencing playback problems, try adjusting the quality or refreshing the page.
Questions for Speakers?
Use the Q&A tab to submit questions that may be addressed in follow-up sessions.
